These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 25577038)

  • 1. Radiolabeled antibodies in prostate cancer: a case study showing the effect of host immunity on antibody bio-distribution.
    Vilhelmsson-Timmermand O; Santos E; Thorek DL; Evans-Axelsson S; Bjartell A; Lilja H; Larson SM; Strand SE; Tran TA; Ulmert D
    Nucl Med Biol; 2015 Apr; 42(4):375-80. PubMed ID: 25577038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Specific localization, gamma camera imaging, and intracellular trafficking of radiolabelled chimeric anti-G(D3) ganglioside monoclonal antibody KM871 in SK-MEL-28 melanoma xenografts.
    Lee FT; Rigopoulos A; Hall C; Clarke K; Cody SH; Smyth FE; Liu Z; Brechbiel MW; Hanai N; Nice EC; Catimel B; Burgess AW; Welt S; Ritter G; Old LJ; Scott AM
    Cancer Res; 2001 Jun; 61(11):4474-82. PubMed ID: 11389078
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preparation and comparative evaluation of 99mTc-labeled 2-iminothiolane modified antibodies and CITC-DTPA immunoconjugates of anti-EGF-receptor antibodies.
    Mishra AK; Iznaga-Escobar N; Figueredo R; Jain VK; Dwarakanath BS; Pérez-Rodríguez R; Sharma RK; Mathew TL
    Methods Find Exp Clin Pharmacol; 2002 Dec; 24(10):653-60. PubMed ID: 12616957
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting HER2: a report on the in vitro and in vivo pre-clinical data supporting trastuzumab as a radioimmunoconjugate for clinical trials.
    Milenic DE; Wong KJ; Baidoo KE; Nayak TK; Regino CA; Garmestani K; Brechbiel MW
    MAbs; 2010; 2(5):550-64. PubMed ID: 20716957
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metal-Chelating Polymers (MCPs) with Zwitterionic Pendant Groups Complexed to Trastuzumab Exhibit Decreased Liver Accumulation Compared to Polyanionic MCP Immunoconjugates.
    Liu P; Boyle AJ; Lu Y; Adams J; Chi Y; Reilly RM; Winnik MA
    Biomacromolecules; 2015 Nov; 16(11):3613-23. PubMed ID: 26469142
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Conjugation Strategy to Modulate Antigen Binding and FcRn Interaction Leads to Improved Tumor Targeting and Radioimmunotherapy Efficacy with an Antibody Targeting Prostate-Specific Antigen.
    Vilhelmsson Timmermand O; Örbom A; Altai M; Zedan W; Holmqvist B; Safi M; Tran TA; Strand SE; Strand J
    Cancers (Basel); 2021 Jul; 13(14):. PubMed ID: 34298682
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intratherapeutic biokinetic measurements, dosimetry parameter estimates, and monitoring of treatment efficacy using cerenkov luminescence imaging in preclinical radionuclide therapy.
    Timmermand OV; Tran TA; Strand SE; Axelsson J
    J Nucl Med; 2015 Mar; 56(3):444-9. PubMed ID: 25655628
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual-Receptor-Targeted Radioimmunotherapy of Human Breast Cancer Xenografts in Athymic Mice Coexpressing HER2 and EGFR Using 177Lu- or 111In-Labeled Bispecific Radioimmunoconjugates.
    Razumienko EJ; Chen JC; Cai Z; Chan C; Reilly RM
    J Nucl Med; 2016 Mar; 57(3):444-52. PubMed ID: 26429962
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Humanization, Radiolabeling and Biodistribution Studies of an IgG
    Strand J; Sjöström K; Lamminmaki UJ; Vilhelmsson Timmermand O; Strand SE; Tran TA
    Pharmaceuticals (Basel); 2021 Dec; 14(12):. PubMed ID: 34959652
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting tomoregulin for radioimmunotherapy of prostate cancer.
    Zhao XY; Schneider D; Biroc SL; Parry R; Alicke B; Toy P; Xuan JA; Sakamoto C; Wada K; Schulze M; Müller-Tiemann B; Parry G; Dinter H
    Cancer Res; 2005 Apr; 65(7):2846-53. PubMed ID: 15805286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the in vivo biodistribution of indium-111 and yttrium-88 labeled dendrimer-1B4M-DTPA and its conjugation with anti-Tac monoclonal antibody.
    Kobayashi H; Wu C; Kim MK; Paik CH; Carrasquillo JA; Brechbiel MW
    Bioconjug Chem; 1999; 10(1):103-11. PubMed ID: 9893971
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of conjugation on the biodistribution of 111In-labelled anti-PAP and anti-PSA monoclonal antibodies examined in nude mice with PC-82 human tumor xenografts.
    Perälä-Heape M; Vihko P; Pelkonen I; Laine A; Vihko R
    In Vivo; 1991; 5(2):159-65. PubMed ID: 1722716
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PD-L1 Antibody Pharmacokinetics and Tumor Targeting in Mouse Models for Infectious Diseases.
    Sandker GGW; Adema G; Molkenboer-Kuenen J; Wierstra P; Bussink J; Heskamp S; Aarntzen EHJG
    Front Immunol; 2022; 13():837370. PubMed ID: 35359962
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re.
    Brouwers AH; van Eerd JE; Frielink C; Oosterwijk E; Oyen WJ; Corstens FH; Boerman OC
    J Nucl Med; 2004 Feb; 45(2):327-37. PubMed ID: 14960657
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravenous injection of an immunoconjugate (anti-PSA-IgG conjugated to 5-fluoro-2'-deoxyuridine) selectively inhibits cell proliferation and induces cell death in human prostate cancer cell tumors grown in nude mice.
    Sinha AA; Quast BJ; Reddy PK; Elson MK; Wilson MJ
    Anticancer Res; 1999; 19(2A):893-902. PubMed ID: 10368631
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pretargeting with bispecific anti-renal cell carcinoma x anti-DTPA(In) antibody in 3 RCC models.
    van Schaijk FG; Oosterwijk E; Molkenboer-Kuenen JD; Soede AC; McBride BJ; Goldenberg DM; Oyen WJ; Corstens FH; Boerman OC
    J Nucl Med; 2005 Mar; 46(3):495-501. PubMed ID: 15750164
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Site-specifically traced drug release and biodistribution of a paclitaxel-antibody conjugate toward improvement of the linker structure.
    Safavy A; Georg GI; Vander Velde D; Raisch KP; Safavy K; Carpenter M; Wang W; Bonner JA; Khazaeli MB; Buchsbaum DJ
    Bioconjug Chem; 2004; 15(6):1264-74. PubMed ID: 15546192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of enhanced permeability effect and different linear energy transfer of radionuclides in a prostate cancer xenograft model.
    Vilhelmsson Timmermand O; Safi M; Holmqvist B; Strand J
    Am J Nucl Med Mol Imaging; 2023; 13(4):147-155. PubMed ID: 37736493
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the biodistribution and tumor targeting of two 99mTc-labeled anti-EGFR nanobodies in mice, using pinhole SPECT/micro-CT.
    Gainkam LO; Huang L; Caveliers V; Keyaerts M; Hernot S; Vaneycken I; Vanhove C; Revets H; De Baetselier P; Lahoutte T
    J Nucl Med; 2008 May; 49(5):788-95. PubMed ID: 18413403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical evaluation of PAC1 targeting with radiolabeled Maxadilan.
    Joosten L; Brom M; Schäfer MKH; Boerman OC; Weihe E; Gotthardt M
    Sci Rep; 2017 May; 7(1):1751. PubMed ID: 28496188
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.